1-2 of 2
Scott Fettner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors

Available to Purchase
Axel-R. Hanauske, Jim Cassidy, Javier Sastre, Claus Bolling, Robert J. Jones, Ashok Rakhit, Scott Fettner, Ulrich Brennscheidt, Andrea Feyereislova, Eduardo Díaz-Rubio
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (2): 523–531.
https://doi.org/10.1158/1078-0432.CCR-06-1627
Published: 25 January 2007
View articletitled, Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors
Open the PDF for Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN-α-2a With and Without Cytarabine in Patients with Chronic Myelogenous Leukemia

Available to Purchase
Moshe Talpaz, Ashok Rakhit, Karen Rittweger, Susan O'Brien, Jorge Cortes, Scott Fettner, Leon Hooftman, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (17): 6247–6255.
https://doi.org/10.1158/1078-0432.CCR-05-0882
Published: 06 September 2005
View articletitled, Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN-α-2a With and Without Cytarabine in Patients with Chronic Myelogenous Leukemia
Open the PDF for Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN-α-2a With and Without Cytarabine in Patients with Chronic Myelogenous Leukemia in another window